| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.
|
N Engl J Med
|
2001
|
5.59
|
|
2
|
Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation.
|
N Engl J Med
|
2001
|
3.98
|
|
3
|
Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia.
|
Biol Blood Marrow Transplant
|
2001
|
2.10
|
|
4
|
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation.
|
Blood
|
2001
|
2.04
|
|
5
|
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis.
|
Leukemia
|
2006
|
1.92
|
|
6
|
Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.
|
J Clin Oncol
|
1994
|
1.67
|
|
7
|
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.
|
Blood
|
1997
|
1.64
|
|
8
|
Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose.
|
Blood
|
1997
|
1.57
|
|
9
|
Chronic kidney disease following non-myeloablative hematopoietic cell transplantation.
|
Am J Transplant
|
2006
|
1.29
|
|
10
|
Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.
|
Clin Cancer Res
|
1997
|
1.27
|
|
11
|
Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation.
|
Biol Blood Marrow Transplant
|
2001
|
1.25
|
|
12
|
Effectiveness of smoking cessation interventions integrated into primary care practice.
|
Med Care
|
1988
|
1.23
|
|
13
|
Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.
|
Cancer Res
|
1988
|
1.22
|
|
14
|
A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
|
J Clin Invest
|
1990
|
1.20
|
|
15
|
Staurosporine-induced apoptosis in cardiomyocytes: A potential role of caspase-3.
|
J Mol Cell Cardiol
|
1998
|
1.17
|
|
16
|
Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up.
|
Hepatology
|
1999
|
1.13
|
|
17
|
Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience.
|
Bone Marrow Transplant
|
2000
|
1.09
|
|
18
|
Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia.
|
J Clin Oncol
|
2001
|
1.08
|
|
19
|
Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin.
|
J Natl Cancer Inst
|
1988
|
1.06
|
|
20
|
Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation.
|
Blood
|
2001
|
1.03
|
|
21
|
Immunomodulatory effects of mixed hematopoietic chimerism: immune tolerance in canine model of lung transplantation.
|
Am J Transplant
|
2009
|
1.02
|
|
22
|
In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.
|
Cancer Res
|
1988
|
1.02
|
|
23
|
Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors.
|
Bone Marrow Transplant
|
2002
|
1.01
|
|
24
|
Cirrhosis of the liver in long-term marrow transplant survivors.
|
Blood
|
1999
|
1.01
|
|
25
|
Synergistic antitumor effects of tumor necrosis factor and gamma-interferon on human colon carcinoma cell lines.
|
Cancer Res
|
1987
|
1.00
|
|
26
|
G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required.
|
Biol Blood Marrow Transplant
|
2001
|
1.00
|
|
27
|
Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.
|
Bone Marrow Transplant
|
2009
|
0.97
|
|
28
|
Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma.
|
J Immunother Emphasis Tumor Immunol
|
1996
|
0.94
|
|
29
|
Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning.
|
Bone Marrow Transplant
|
2005
|
0.93
|
|
30
|
Anaplastic Wilms' tumor: clinical and pathologic studies.
|
J Clin Oncol
|
1985
|
0.92
|
|
31
|
Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro.
|
J Med Chem
|
1991
|
0.92
|
|
32
|
Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2001
|
0.91
|
|
33
|
Mechanisms involved in the hyperglycemic response induced by clonidine and other alpha-2 adrenoceptor agonists.
|
J Pharmacol Exp Ther
|
1984
|
0.90
|
|
34
|
Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
|
Clin Cancer Res
|
1996
|
0.89
|
|
35
|
Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens.
|
Bone Marrow Transplant
|
2008
|
0.89
|
|
36
|
Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation.
|
Blood
|
2000
|
0.89
|
|
37
|
Assignment of scores for the hematopoietic cell transplantation comorbidity index: integer vs exact weights.
|
Bone Marrow Transplant
|
2010
|
0.87
|
|
38
|
A phase I study of 5-fluorouracil, leucovorin and levamisole.
|
Cancer Chemother Pharmacol
|
1997
|
0.87
|
|
39
|
Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center.
|
Bone Marrow Transplant
|
2012
|
0.86
|
|
40
|
Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.
|
Cancer Res
|
1989
|
0.86
|
|
41
|
Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.
|
Clin Cancer Res
|
1995
|
0.86
|
|
42
|
Comorbidity burden in patients with chronic GVHD.
|
Bone Marrow Transplant
|
2013
|
0.86
|
|
43
|
Characterization of the synergistic antiproliferative effects of interferon-gamma and tumor necrosis factor on human colon carcinoma cell lines.
|
J Interferon Res
|
1990
|
0.86
|
|
44
|
Phase 1 clinical evaluation of recombinant interleukin-2.
|
Prog Clin Biol Res
|
1987
|
0.85
|
|
45
|
Increased endothelin excretion in rats with renal failure induced by partial nephrectomy.
|
Br J Pharmacol
|
1991
|
0.85
|
|
46
|
Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion.
|
J Clin Oncol
|
1987
|
0.84
|
|
47
|
Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma.
|
Cancer Invest
|
1991
|
0.83
|
|
48
|
Comparison of spontaneous and induced mutation rates in an immortalized human bronchial epithelial cell line and its tumorigenic derivative.
|
Oncology
|
1997
|
0.83
|
|
49
|
Plasma lipoprotein changes in humans induced by beta-interferon.
|
Atherosclerosis
|
1987
|
0.83
|
|
50
|
Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2.
|
J Biol Response Mod
|
1990
|
0.83
|
|
51
|
Effect of nifedipine on cyclosporine A-induced nephrotoxicity, urinary endothelin excretion and renal endothelin receptor number.
|
Eur J Pharmacol
|
1991
|
0.82
|
|
52
|
The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.
|
J Biol Response Mod
|
1988
|
0.81
|
|
53
|
Antiproliferative effects of interferons -alpha and -beta in combination with 5-fluorouracil, cisplatin, and cis- and trans-retinoic acid in three human lung carcinoma cell lines.
|
J Interferon Res
|
1993
|
0.81
|
|
54
|
Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
|
Cancer Res
|
1990
|
0.81
|
|
55
|
Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor.
|
Cancer
|
1992
|
0.81
|
|
56
|
Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor.
|
J Clin Oncol
|
1997
|
0.80
|
|
57
|
Modulation of U937 cell adhesion to vascular endothelial cells by cyclic AMP.
|
Life Sci
|
1991
|
0.80
|
|
58
|
A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans.
|
Cancer Res
|
1993
|
0.80
|
|
59
|
Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy.
|
J Clin Oncol
|
1998
|
0.80
|
|
60
|
Endothelin and platelet function.
|
Thromb Res
|
1990
|
0.79
|
|
61
|
Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion.
|
Cancer Invest
|
1989
|
0.79
|
|
62
|
Phase I trial of combinations of recombinant interferons beta(ser) and gamma in patients with advanced malignancy.
|
Cancer Treat Rep
|
1987
|
0.78
|
|
63
|
Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104).
|
Clin Cancer Res
|
1999
|
0.78
|
|
64
|
Abdominal relapses in irradiated second National Wilms' Tumor Study patients.
|
J Clin Oncol
|
1984
|
0.78
|
|
65
|
Selective estrogen receptor modulator idoxifene inhibits smooth muscle cell proliferation, enhances reendothelialization, and inhibits neointimal formation in vivo after vascular injury.
|
Circulation
|
2000
|
0.78
|
|
66
|
Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.
|
J Natl Cancer Inst
|
1988
|
0.78
|
|
67
|
Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival.
|
J Clin Oncol
|
1996
|
0.78
|
|
68
|
The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2.
|
Cancer
|
1990
|
0.77
|
|
69
|
Tissue-type plasminogen activator and streptokinase induce platelet hyperaggregability in the rabbit.
|
Thromb Res
|
1987
|
0.77
|
|
70
|
DLA-DQB1 alleles and bone marrow transplantation experiments in narcoleptic dogs.
|
Tissue Antigens
|
2000
|
0.77
|
|
71
|
Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.
|
J Clin Oncol
|
1997
|
0.77
|
|
72
|
Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma.
|
Eur J Cancer
|
1996
|
0.76
|
|
73
|
Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation.
|
Biol Blood Marrow Transplant
|
1998
|
0.76
|
|
74
|
Endotoxin-mediated changes in plasma endothelin concentrations, renal endothelin receptor and renal function.
|
Pharmacology
|
1994
|
0.76
|
|
75
|
Randomized phase II-III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell cancer of the lung.
|
J Natl Cancer Inst
|
1989
|
0.76
|
|
76
|
Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells.
|
J Mol Cell Cardiol
|
1998
|
0.76
|
|
77
|
Phase I trial of human lymphoblastoid interferon with whole body hyperthermia in advanced cancer.
|
Cancer Res
|
1989
|
0.76
|
|
78
|
Effects of combinations of interferon-beta ser and interferon-gamma on interferon-inducible proteins and on the cell cycle.
|
J Biol Response Mod
|
1990
|
0.75
|
|
79
|
Tumor-infiltrating lymphocytes and interleukin-2 in melanomas.
|
N Engl J Med
|
1989
|
0.75
|
|
80
|
Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies.
|
Invest New Drugs
|
1993
|
0.75
|
|
81
|
A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
|
Semin Oncol
|
1994
|
0.75
|
|
82
|
Phase II trial of a combination of interferon-beta ser and interferon-gamma in patients with advanced malignant melanoma.
|
J Interferon Res
|
1988
|
0.75
|
|
83
|
Clinical testing of IL-2: in vivo administration of IL-2 induces IL-2 dependent non-MHC-restricted cytotoxicity (NRC).
|
Prog Clin Biol Res
|
1987
|
0.75
|
|
84
|
A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer.
|
J Immunother Emphasis Tumor Immunol
|
1993
|
0.75
|
|
85
|
A pilot study of short-course, high-dose cytosine arabinoside, etoposide, and cisplatin in refractory, aggressive-histology, non-Hodgkin's lymphomas.
|
Am J Clin Oncol
|
1989
|
0.75
|